BiotechTube

Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Conditions

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Trial Timeline

Dec 24, 2015 โ†’ Jun 3, 2021

NCT ID
NCT02625610

About Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine

Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine is a phase 3 stage product being developed by Merck for Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction. The current trial status is completed. This product is registered under clinical trial identifier NCT02625610. Target conditions include Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02625610Phase 3Completed

Competing Products

20 competing products in Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-ฮฑ-NET + [212Pb]VMT-ฮฑ-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
LenvatinibEisaiPhase 2
52
LenvatinibEisaiPhase 1
33
Nivolumab + EverolimusOno PharmaceuticalPhase 3
77
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
77
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358Jiangsu Hengrui MedicinePhase 1/2
41
Camrelizumab + HAIC + TKIJiangsu Hengrui MedicinePhase 2
52
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
77
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + OxaliplatinAbbViePhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
MavencladยฎApproved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85